https://m2.mtmt.hu/ hun 2026-09-20 17:23 JournalArticle 32495289 VALIDATED true Megosztott utolsó szerzőség 0 false 2026-09-14T16:37:58.947+0000 2026-06-15T08:30:41.181+0000 2021-11-16T09:50:37.547+0000 true 10063433 Buzási Éva /api/admin/10063433 Admin Buzási Éva (Kaposi Mór Kház 5-ös admin) true 10063433 2026-05-04T13:10:42.292+0000 2026-05-04T13:10:42.292+0000 2021-11-23T13:37:45.902+0000 true 10051765 Fölkerné Csernyik Rita /api/admin/10051765 Admin Fölkerné Csernyik Rita (PTE 4-es admin - INAKTÍV) true 10051765 2022-04-29T19:32:19.112+0000 true 10039043 Milánkovics Róbert /api/admin/10039043 Admin Milánkovics Róbert (PTE ÁOK admin 4) true 10039043 Admin 10065569 /api/admin/10065569 Pécsi Éva (MTMT Közp 2,3, admin) Pécsi Éva true true 2023-06-05T15:04:38.794+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Kiss, Szabolcs true true /api/journal/10019966 REVIEWED SCIENTIFIC REPORTS 2045-2322 true false 10019966 false 10019966 true 2045-2322 Journal FOREIGN 11 1 21916 21916 12 2021 Funding 2005432 /api/funding/2005432 Átfogó fejlesztések a Pécsi Tudományegyetemen az intelligens szakosodás megvalósítása érdekében(EFOP-3.6.1-16-2016-00004) Támogató: EFOP false true Funding 2005433 /api/funding/2005433 (2.3.4-15-2020-00010) Támogató: GINOP false true Funding 2005434 /api/funding/2005434 (ÚNKP-20-3) false true true true INTERNATIONAL 2021 true true true false true false GOLD 2026-09-14 true https://doi.org/10.1038/s41598-021-01440-x 29 0 25 23 2 23 25 22 20 23 23 22 22 27 2 0 29 27 25 23 0 4 4 Folyóiratcikk Journal Article 24 25 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 1 Egyéb Miscellaneous 29 3 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2022 0 4 4 4 4 2023 0 7 7 7 7 2024 0 7 5 7 5 2025 0 7 7 7 7 2026 0 4 4 4 4 D1 A nemzetközi false 10043311,10084215 false false false 2021-11-15T09:52:13.799+0000 I. sz. Belgyógyászati Klinika (PTE / ÁOK); Klinikai Orvostudományi Doktori Iskola (SZTE / DI); Transzlációs Medicina Intézet (PTE / ÁOK); Transzlációs Medicina Központ (SE / KSZE) 9 34 4 11 0 true 10065569 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 99409752 /api/authorship/99409752 Kiss, Szabolcs [Kiss, Szabolcs (Gasztroenterológi...), szerző] Klinikai Orvostudományi Doktori Iskola (SZTE / DI) 1 0.09090909 true false false Author 10070369 /api/author/10070369 Kiss Szabolcs (Gasztroenterológia, hematológia) Kiss Szabolcs true true Kiss Szabolcs true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 99409753 /api/authorship/99409753 Gede, Noémi [Gede, Noémi (Egészségtudomány), szerző] Transzlációs Medicina Intézet (PTE / ÁOK) 2 0.09090909 false false false Author 10048360 /api/author/10048360 Gede Noémi (Egészségtudomány) Gede Noémi true 10048360 true Gede Noémi true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 99409754 /api/authorship/99409754 Hegyi, Péter [Hegyi, Péter (Gasztroenterológia), szerző] Transzlációs Medicina Központ (SE / KSZE) 3 0.09090909 false false false Author 10002629 /api/author/10002629 Hegyi Péter (Gasztroenterológia) Hegyi Péter true 10002629 true Hegyi Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 99409755 /api/authorship/99409755 Nagy, Bettina 4 0.09090909 false false false Nagy Bettina true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 99409756 /api/authorship/99409756 Deák, Rita 5 0.09090909 false false false Deák Rita true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 99409757 /api/authorship/99409757 Dembrovszky, Fanni [Dembrovszky, Fanni (Általános orvos), szerző] Transzlációs Medicina Intézet (PTE / ÁOK) 6 0.09090909 false false false Author 10070652 /api/author/10070652 Dembrovszky Fanni (Általános orvos) Dembrovszky Fanni true true Dembrovszky Fanni true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 99409758 /api/authorship/99409758 Bunduc, Stefania [Bunduc, Stefania (Gastroenterology), szerző] 7 0.09090909 false false false Author 10084215 /api/author/10084215 Bunduc Stefania (Gastroenterology) Bunduc Stefania true true Bunduc Stefania true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 99409759 /api/authorship/99409759 Erőss, Bálint [Erőss, Bálint Mihály (Gasztroenterológia), szerző] Transzlációs Medicina Intézet (PTE / ÁOK) 8 0.09090909 false false false Author 10064235 /api/author/10064235 Erőss Bálint Mihály (Gasztroenterológia) Erőss Bálint Mihály true 10064235 true Erőss Bálint true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 99409760 /api/authorship/99409760 Leiner, Tamás [Leiner, Tamás (Aneszteziológia é...), szerző] 9 0.09090909 false false false Author 10049460 /api/author/10049460 Leiner Tamás (Aneszteziológia és Intenzív Terápia) Leiner Tamás true 10049460 true Leiner Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 99409761 /api/authorship/99409761 Szakács, Zsolt** [Szakács, Zsolt (Transzlációs Medi...), szerző] I. sz. Belgyógyászati Klinika (PTE / ÁOK) 10 0.091 false true false Author 10062396 /api/author/10062396 Szakács Zsolt (Transzlációs Medicina) Szakács Zsolt true 10062396 true Szakács Zsolt true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 99409762 /api/authorship/99409762 Alizadeh, Hussain ✉ [Alizadeh, Hussain (Belgyógyászat-Hem...), szerző] I. sz. Belgyógyászati Klinika (PTE / ÁOK) 11 0.091 false true true Author 10043311 /api/author/10043311 Alizadeh Hussain (Belgyógyászat-Hematológia-Klinikai onkológia, Klinikai farmakológia) Alizadeh Hussain true 10043311 true Alizadeh Hussain true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 20193938 /api/publicationidentifier/20193938 DOI: 10.1038/s41598-021-01440-x PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1038/s41598-021-01440-x https://doi.org/10.1038/s41598-021-01440-x false true PublicationIdentifier 20302810 /api/publicationidentifier/20302810 WoS: 000716666700050 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000716666700050 https://www.webofscience.com/wos/woscc/full-record/000716666700050 false true PublicationIdentifier 20193940 /api/publicationidentifier/20193940 Scopus: 85118683603 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85118683603 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85118683603 false true PublicationIdentifier 20221606 /api/publicationidentifier/20221606 PubMed: 34754015 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 34754015 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34754015&dopt=Abstract true true PublicationIdentifier 32500966 /api/publicationidentifier/32500966 Google scholar: 9294409837186112592 PlainSource 12 /api/publicationsource/12 Google scholar PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Google scholar http://scholar.Google.com/scholar?hl=en&lr=&cluster=@@@ true true 12 true 9294409837186112592 http://scholar.Google.com/scholar?hl=en&lr=&cluster=9294409837186112592 true true Classification 12358 /api/classification/12358 Metaanalízis true true Keyword 3375201 /api/keyword/3375201 [Meta-analysis] true true MtaRating 519359 /api/mtarating/519359 IX. Szociológiai Tudományos Bizottság:A nemzetközi SCIENTIFIC REPORTS 2045-2322 RatingType 10007 /api/ratingtype/10007 IX. Szociológiai Tudományos Bizottság SZTB Institute 14102 /api/institute/14102 Szociológiai Tudományos Bizottság IXGJO SZTB [1901-] 0 false true false Szociológiai Tudományos Bizottság Committee on Sociology true 14102 true true true A nemzetközi true 19359 true MtaRating 11551161 /api/mtarating/11551161 IX. Regionális Tudományok Bizottsága:B nemzetközi SCIENTIFIC REPORTS 2045-2322 RatingType 10010 /api/ratingtype/10010 IX. Regionális Tudományok Bizottsága RegTB Institute 14100 /api/institute/14100 Regionális Tudományok Bizottsága IXGJO RTB [1901-] 0 false true false Regionális Tudományok Bizottsága Committee on Regional Studies true 14100 true true true B nemzetközi false true SjrRating 11184995 /api/sjrrating/11184995 sjr:D1 (2021) Scopus - Multidisciplinary SCIENTIFIC REPORTS 2045-2322 11 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1000 /api/classificationexternal/1000 Scopus - Multidisciplinary true 1000 true D1 DIRECT true true Reference 25106919 /api/reference/25106919 1. Rajkumar, S. V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. 95, 548–567. https://doi.org/10.1002/ajh.25791 (2020)., DOI: 10.1002/ajh.25791 1 10.1002/ajh.25791 false true Reference 25106920 /api/reference/25106920 2. Kazandjian, D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin. Oncol. 43, 676–681. https://doi.org/10.1053/j.seminoncol.2016.11.004 (2016)., DOI: 10.1053/j.seminoncol.2016.11.004 2 10.1053/j.seminoncol.2016.11.004 false true Reference 25106921 /api/reference/25106921 3. Merrill, R. M. & Dearden, K. A. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States?. Cancer Causes Control 15, 1027–1034. https://doi.org/10.1007/s10552-004-1324-5 (2004)., DOI: 10.1007/s10552-004-1324-5 3 10.1007/s10552-004-1324-5 false true Reference 25106922 /api/reference/25106922 4. Thanendrarajan, S. et al. Monoclonal antibody therapy in multiple myeloma: Where do we stand and where are we going?. Immunotherapy 8, 367–384. https://doi.org/10.2217/imt.15.118 (2016)., DOI: 10.2217/imt.15.118 4 10.2217/imt.15.118 false true Reference 25106923 /api/reference/25106923 5. Plesner, T. & Krejcik, J. Daratumumab for the treatment of multiple myeloma. Front. Immunol. 9, 1228–1228. https://doi.org/10.3389/fimmu.2018.01228 (2018)., DOI: 10.3389/fimmu.2018.01228 5 10.3389/fimmu.2018.01228 false true Reference 25106924 /api/reference/25106924 6. Nastoupil, L. J. When to use targeted therapy for the treatment of follicular lymphoma. Curr. Hematol. Malig. Rep. 16, 45–51. https://doi.org/10.1007/s11899-021-00617-5 (2021)., DOI: 10.1007/s11899-021-00617-5 6 10.1007/s11899-021-00617-5 false true Reference 25106925 /api/reference/25106925 7. Xu, W. et al. Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis. Eur. J. Haematol. 103, 542–551. https://doi.org/10.1111/ejh.13317 (2019)., DOI: 10.1111/ejh.13317 7 10.1111/ejh.13317 false true Reference 25106926 /api/reference/25106926 8. Wang, Y., Li, Y. & Chai, Y. Efficacy and safety of daratumumab in the treatment of multiple myeloma: A systematic review and meta-analysis. J. Int. Med. Res. 49, 03000605211038135. https://doi.org/10.1177/03000605211038135 (2021)., DOI: 10.1177/03000605211038135 8 10.1177/03000605211038135 false true Reference 25106927 /api/reference/25106927 9. Giri, S. et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: A systematic review and meta-analysis. JAMA Oncol. 6, 1–8. https://doi.org/10.1001/jamaoncol.2020.4338 (2020)., DOI: 10.1001/jamaoncol.2020.4338 9 10.1001/jamaoncol.2020.4338 false true Reference 25106928 /api/reference/25106928 10. Cao, C., Zhou, X. & Ma, Q. Daratumumab provides a survival benefit in relapsed and refractory multiple myeloma, independent of baseline clinical characteristics: A meta-analysis. Pharmacol. Res. Perspect. 9, e00797. https://doi.org/10.1002/prp2.797 (2021)., DOI: 10.1002/prp2.797 10 10.1002/prp2.797 false true Reference 25106929 /api/reference/25106929 11. Premkumar, V., Pan, S., Lentzsch, S. & Bhutani, D. Use of daratumumab in high risk multiple myeloma: A meta-analysis. eJHeam 1, 267–271. https://doi.org/10.1002/jha2.47 (2020)., DOI: 10.1002/jha2.47 11 10.1002/jha2.47 false true Reference 25106930 /api/reference/25106930 12. Chong, L. L. et al. Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 159, 103211. https://doi.org/10.1016/j.critrevonc.2020.103211 (2021)., DOI: 10.1016/j.critrevonc.2020.103211 12 10.1016/j.critrevonc.2020.103211 false true Reference 25106931 /api/reference/25106931 13. Mohyuddin, G. R. et al. Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: Systematic review and meta-analysis. Leuk. Lymphoma 61, 2519–2522. https://doi.org/10.1080/10428194.2020.1772475 (2020)., DOI: 10.1080/10428194.2020.1772475 13 10.1080/10428194.2020.1772475 false true Reference 25106932 /api/reference/25106932 14. Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ (Clin. Res. Ed.) 372, n71. https://doi.org/10.1136/bmj.n71 (2021)., DOI: 10.1136/bmj.n71 14 10.1136/bmj.n71 false true Reference 25106933 /api/reference/25106933 15. McHugh, M. L. Interrater reliability: The kappa statistic. Biochem. Med. (Zagreb) 22, 276–282 (2012)., DOI: 10.11613/BM.2012.031 15 10.11613/BM.2012.031 false true Reference 25106934 /api/reference/25106934 16. Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ (Clin. Res. Ed.) 366, l4898. https://doi.org/10.1136/bmj.l4898 (2019)., DOI: 10.1136/bmj.l4898 16 10.1136/bmj.l4898 false true Reference 25106935 /api/reference/25106935 17. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials 7, 177–188. https://doi.org/10.1016/0197-2456(86)90046-2 (1986)., DOI: 10.1016/0197-2456(86)90046-2 17 10.1016/0197-2456(86)90046-2 false true Reference 25106936 /api/reference/25106936 18. Jonathan J Deeks, Julian PT Higgins, Douglas G Altman & Group, o. b. o. t. C. S. M. (2021). 18 false true Reference 25106937 /api/reference/25106937 19. Dimopoulos, M. et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study. Lancet 396, 186–197 (2020)., DOI: 10.1016/S0140-6736(20)30734-0 19 10.1016/S0140-6736(20)30734-0 false true Reference 25106938 /api/reference/25106938 20. Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319–1331. https://doi.org/10.1056/NEJMoa1607751 (2016)., DOI: 10.1056/NEJMoa1607751 20 10.1056/NEJMoa1607751 false true Reference 25106939 /api/reference/25106939 21. Dimopoulos, M. A. et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial. Lancet Oncol. 22, 801–812. https://doi.org/10.1016/s1470-2045(21)00128-5 (2021)., DOI: 10.1016/s1470-2045(21)00128-5 21 10.1016/s1470-2045(21)00128-5 false true Reference 25106940 /api/reference/25106940 22. Facon, T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 380, 2104–2115. https://doi.org/10.1056/NEJMoa1817249 (2019)., DOI: 10.1056/NEJMoa1817249 22 10.1056/NEJMoa1817249 false true Reference 25106941 /api/reference/25106941 23. Kaufman, J. L. et al. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: A cytogenetic subgroup analysis of POLLUX. Blood Cancer J. 10, 111. https://doi.org/10.1038/s41408-020-00375-2 (2020)., DOI: 10.1038/s41408-020-00375-2 23 10.1038/s41408-020-00375-2 false true Reference 25106942 /api/reference/25106942 24. Lu, J. et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in chinese patients with relapsed or refractory multiple myeloma: Phase 3 LEPUS (MMY3009) study. Clin. Lymphoma Myeloma Leuk. 21, e699–e709. https://doi.org/10.1016/j.clml.2021.04.012 (2021)., DOI: 10.1016/j.clml.2021.04.012 24 10.1016/j.clml.2021.04.012 false true Reference 25106943 /api/reference/25106943 25. Mateos, M. V. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial. Lancet 395, 132–141. https://doi.org/10.1016/s0140-6736(19)32956-3 (2020)., DOI: 10.1016/s0140-6736(19)32956-3 25 10.1016/s0140-6736(19)32956-3 false true Reference 25106944 /api/reference/25106944 26. Mateos, M. V. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N. Engl. J. Med. 378, 518–528. https://doi.org/10.1056/NEJMoa1714678 (2018)., DOI: 10.1056/NEJMoa1714678 26 10.1056/NEJMoa1714678 false true Reference 25106945 /api/reference/25106945 27. Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study. Lancet 394, 29–38. https://doi.org/10.1016/s0140-6736(19)31240-1 (2019)., DOI: 10.1016/s0140-6736(19)31240-1 27 10.1016/s0140-6736(19)31240-1 false true Reference 25106946 /api/reference/25106946 28. Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 754–766. https://doi.org/10.1056/NEJMoa1606038 (2016)., DOI: 10.1056/NEJMoa1606038 28 10.1056/NEJMoa1606038 false true Reference 25106947 /api/reference/25106947 29. Voorhees, P. M. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial. Blood 136, 936–945. https://doi.org/10.1182/blood.2020005288 (2020)., DOI: 10.1182/blood.2020005288 29 10.1182/blood.2020005288 false true Reference 25106948 /api/reference/25106948 30. Weisel, K. et al. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk. J. Hematol. Oncol. 13, 115. https://doi.org/10.1186/s13045-020-00948-5 (2020)., DOI: 10.1186/s13045-020-00948-5 30 10.1186/s13045-020-00948-5 false true Reference 25106949 /api/reference/25106949 31. Joseph, N. S., Gentili, S., Kaufman, J. L., Lonial, S. & Nooka, A. K. High-risk multiple myeloma: Definition and management. Clin. Lymphoma Myeloma Leukemia 17S, S80–S87. https://doi.org/10.1016/j.clml.2017.02.018 (2017)., DOI: 10.1016/j.clml.2017.02.018 31 10.1016/j.clml.2017.02.018 false true Reference 25106950 /api/reference/25106950 32. Bahlis, N. et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant: Updated analysis of maia. Blood 134, 1875–1875. https://doi.org/10.1182/blood-2019-123426%JBlood (2019)., DOI: 10.1182/blood-2019-123426%JBlood 32 10.1182/blood-2019-123426%JBlood false true Reference 25106951 /api/reference/25106951 33. Chanan-Khan, A. A. & Giralt, S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28, 2612–2624. https://doi.org/10.1200/jco.2009.25.4250 (2010)., DOI: 10.1200/jco.2009.25.4250 33 10.1200/jco.2009.25.4250 false true Reference 25106952 /api/reference/25106952 34. Kapoor, P. et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 31, 4529–4535. https://doi.org/10.1200/JCO.2013.49.0086 (2013)., DOI: 10.1200/JCO.2013.49.0086 34 10.1200/JCO.2013.49.0086 false true Reference 25106953 /api/reference/25106953 35. Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132, 2456–2464. https://doi.org/10.1182/blood-2018-06-858613 (2018)., DOI: 10.1182/blood-2018-06-858613 35 10.1182/blood-2018-06-858613 false true Reference 25106954 /api/reference/25106954 36. Htut, T. W. et al. Incidence of second primary malignancies and peripheral sensory neuropathy in patients with multiple myeloma receiving daratumumab containing regimen. Blood 134, 5550–5550. https://doi.org/10.1182/blood-2019-123156%JBlood (2019)., DOI: 10.1182/blood-2019-123156%JBlood 36 10.1182/blood-2019-123156%JBlood false true Reference 25106955 /api/reference/25106955 37. Jain, A. & Ramasamy, K. Evolving role of daratumumab: From backbencher to frontline agent. Clin. Lymphoma Myeloma Leuk. 20, 572–587. https://doi.org/10.1016/j.clml.2020.03.010 (2020)., DOI: 10.1016/j.clml.2020.03.010 37 10.1016/j.clml.2020.03.010 false true Reference 25106956 /api/reference/25106956 38. Poh, C., Keegan, T. & Rosenberg, A. S. Second primary malignancies in multiple myeloma: A review. Blood Rev. 46, 100757. https://doi.org/10.1016/j.blre.2020.100757 (2021)., DOI: 10.1016/j.blre.2020.100757 38 10.1016/j.blre.2020.100757 false true Reference 25106957 /api/reference/25106957 39. Dong, C. & Hemminki, K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: A search for common mechanisms. Br. J. Cancer 85, 997–1005. https://doi.org/10.1038/sj.bjc.6691998 (2001)., DOI: 10.1038/sj.bjc.6691998 39 10.1038/sj.bjc.6691998 false true /api/publication/32495289 Kiss Szabolcs et al. Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials. (2021) SCIENTIFIC REPORTS 2045-2322 11 1<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10070369"><a href="/gui2/?type=authors&mode=browse&sel=10070369" target="_blank">Kiss Szabolcs (<span class="authorship-author-name">Kiss Szabolcs</span> <span class="authorAux-mtmt"> Gasztroenterológia, hematológia</span>) </a> </span> <span class="author-affil"><span title="Szegedi Tudományegyetem">SZTE</span>/<span title="Doktori Iskolák">DI</span>/Klinikai Orvostudományi Doktori Iskola</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10048360"><a href="/gui2/?type=authors&mode=browse&sel=10048360" target="_blank">Gede Noémi (<span class="authorship-author-name">Gede Noémi</span> <span class="authorAux-mtmt"> Egészségtudomány</span>) </a> </span> <span class="author-affil"><span title="Pécsi Tudományegyetem">PTE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002629"><a href="/gui2/?type=authors&mode=browse&sel=10002629" target="_blank">Hegyi Péter (<span class="authorship-author-name">Hegyi Péter</span> <span class="authorAux-mtmt"> Gasztroenterológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Transzlációs Medicina Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Nagy Bettina </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Deák Rita </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10070652"><a href="/gui2/?type=authors&mode=browse&sel=10070652" target="_blank">Dembrovszky Fanni (<span class="authorship-author-name">Dembrovszky Fanni</span> <span class="authorAux-mtmt"> Általános orvos</span>) </a> </span> <span class="author-affil"><span title="Pécsi Tudományegyetem">PTE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10084215"><a href="/gui2/?type=authors&mode=browse&sel=10084215" target="_blank">Bunduc Stefania (<span class="authorship-author-name">Bunduc Stefania</span> <span class="authorAux-mtmt"> Gastroenterology</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10064235"><a href="/gui2/?type=authors&mode=browse&sel=10064235" target="_blank">Erőss Bálint (<span class="authorship-author-name">Erőss Bálint Mihály</span> <span class="authorAux-mtmt"> Gasztroenterológia</span>) </a> </span> <span class="author-affil"><span title="Pécsi Tudományegyetem">PTE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10049460"><a href="/gui2/?type=authors&mode=browse&sel=10049460" target="_blank">Leiner Tamás (<span class="authorship-author-name">Leiner Tamás</span> <span class="authorAux-mtmt"> Aneszteziológia és Intenzív Terápia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10062396"><a href="/gui2/?type=authors&mode=browse&sel=10062396" target="_blank">Szakács Zsolt^** (<span class="authorship-author-name">Szakács Zsolt</span> <span class="authorAux-mtmt"> Transzlációs Medicina</span>) </a> </span> <span class="author-affil"><span title="Pécsi Tudományegyetem">PTE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/I. sz. Belgyógyászati Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10043311"><a href="/gui2/?type=authors&mode=browse&sel=10043311" target="_blank">Alizadeh Hussain ✉ (<span class="authorship-author-name">Alizadeh Hussain</span> <span class="authorAux-mtmt"> Belgyógyászat-Hematológia-Klinikai onkológia, K...</span>) </a> </span> <span class="author-affil"><span title="Pécsi Tudományegyetem">PTE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/I. sz. Belgyógyászati Klinika</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32495289" target="_blank">Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials</a></div> <div> <span class="journal-title">SCIENTIFIC REPORTS</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2045-2322">2045-2322</a>)</span>: <span class="journal-volume">11</span> <span class="journal-issue">1</span> <span class="page"> Paper 21916. 12 p. </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1038/s41598-021-01440-x" target="_blank" href="https://doi.org/10.1038/s41598-021-01440-x"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000716666700050" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000716666700050"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85118683603" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85118683603"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="34754015" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34754015&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:black" title="9294409837186112592" target="_blank" href="http://scholar.Google.com/scholar?hl=en&lr=&cluster=9294409837186112592"> Google scholar </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Multidisciplinary&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Szociológiai Tudományos Bizottság IXGJO SZTB [1901-]&nbsp;&nbsp;&nbsp;A nemzetközi</div> <div class="journal-subject">Regionális Tudományok Bizottsága IXGJO RTB [1901-]&nbsp;&nbsp;&nbsp;B nemzetközi</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 29</span> | Független: 27 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 22 | Scopus jelölt:&nbsp;20 | WoS/Scopus jelölt:&nbsp;23 | DOI jelölt:&nbsp;25 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;32495289&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 4 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 32495289</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> Átfogó fejlesztések a Pécsi Tudományegyetemen az intelligens szakosodás megvalósítása érdekében(EFOP-3.6.1-16-2016-00004) Támogató: EFOP, (2.3.4-15-2020-00010) Támogató: GINOP, (ÚNKP-20-3) </div> <div class="lastModified">Utolsó módosítás: 2026.06.15. 10:30 Milánkovics Róbert (PTE ÁOK admin 4) </div> <div class="lockedBy">Központi kezelésű 2023.06.05. 17:04 Pécsi Éva (MTMT Közp 2,3, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Megosztott utolsó szerzőség</pre> </div></div>